PainQx Inc.

PainQx operates at the intersection of AI, medical devices, neurological measurement, diagnostics, and clinical-trial software. Its differentiation is the attempt to convert EEG signals into an objective, scaled measure of pain intensity and neurological side effects, with outputs designed for both clinical workflows and drug- or device-development endpoints. That focus separates it conceptually from general patient-reported outcome tools, conventional pain scales, and digital therapeutics that primarily deliver treatment rather than measurement. The company’s apparent competitive challenge is therefore less about category breadth and more about validation, regulatory execution, clinical adoption, and the reproducibility of its biomarker across pain conditions and trial settings. Its New York base, small employee band of one to ten people, and $3.84 million in disclosed funding indicate an early-stage profile.

PainQx was founded in 2015 and appears to have progressed through an early translational and clinical-development path. It raised a $1.6 million seed round on Aug 21, 2018, alongside two non-equity assistance events dated Aug 31, 2018 and Aug 1, 2020. A further $736,377 seed round on Apr 22, 2021 was followed by a $1.5 million grant on Jun 9, 2021, making the grant the latest recorded financing and bringing total disclosed funding to $3,836,377. The sequence suggests movement from company formation and technology development toward validation of an EEG-based pain biomarker and support for clinical or regulatory work. Its products—the PainQx ALGOS System and cloud-based processing service—indicate an effort to combine hardware or device functionality with recurring software-enabled analysis. Growth therefore appears technically focused but difficult to quantify commercially.